A University of Cincinnati Venture Lab-backed business is exploring minimally invasive technologies to treat musculoskeletal problems that might repair damaged tissue with $6 million in investment, including $2 million from the US Department of Defense.
Amplicore, a Mason, Ohio-based firm, is developing a number of solutions to treat osteoarthritis, cartilage degradation, degenerative disc disease, and acute meniscus tears in joints. The company’s injectable treatments provide optimism that, in the not-too-distant future, wear and tear on joints will be addressed with a regenerative method that eliminates the need for intrusive operations and addictive medicines.
“We recognized our medicine, a distinct type of therapy, from our study and quickly saw its promise,” said Chia-Ying James Lin, PhD, Amplicore’s founder, president, and CEO. “It’s a lot safer medicine, and our study shows that it can help with not only pain reduction but also tissue regeneration.”
Amplicore is one of the firms that came out of UC’s Venture Lab and got seed money as part of the program.
The Venture Lab at UC accelerates and simplifies the process of starting a new business from the ground up. The Venture Lab helps entrepreneurs create new businesses by connecting them with talent and money.